If this message does not display properly, please click here to launch your browser
| Biosimilar Monoclonal Antibodies: What will be the Main Drivers and Constraints of Uptake for Oncologists? — An Analyst Call from Decision Resources’ Biosimilars Advisory Service | |||
Based on Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, Decision Resources is offering an exclusive analyst call entitled Biosimilar Monoclonal Antibodies: What will be the Main Drivers and Constraints of Uptake for Oncologists? This analyst call is open ONLY to subscribers of this module of the Biosimilars Advisory Service. Please contact us to learn how you can purchase this service and attend the analyst call. Decision Resources expects biosimilar versions of monoclonal antibodies (MAbs) used in oncology to erode $5.6 billion in brand sales in 2019 across the U.S., EU5 (France, Germany, Italy, Spain, United Kingdom) and Japan markets. Although biosimilar MAbs are difficult to manufacture because of their complex structure and glycosylation patterns, the sales associated with branded MAbs in oncology ($13.8 billion in 2009 alone) represent a lucrative market opportunity for biosimilar manufacturers. Because of their lower clinical trial requirements, oncologists, compared with other surveyed specialties, will be the most aggressive in adopting biosimilars. Decision Resources expects that competition between branded and biosimilar MAbs, as well as payer pressure to use biosimilars, will contribute to substantial erosion of brand sales. The Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German solid-tumor oncologists and hematologist-oncologists to highlight the key expectations that will drive or constrain biosimilar adoption. This analyst call, presented by Decision Resources Analyst Cindy Fung, Ph.D., will answer the following questions:
Dr. Fung will conduct a live Q & A session at the end of the presentation. Registration: Biosimilars Advisory Service Analyst Call Biosimilar Monoclonal Antibodies: What will be the Main Drivers and Constraints of Uptake for Oncologists? October 12, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase the Biosimilars Advisory Service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
